MedinCell begins first Covid-19 clinical study with Ivermectin

This article was originally published here

The randomised, double-blind, exploratory phase I trial A has been designed to evaluate the pharmacokinetic profile, safety and tolerability of a continuous daily dosing regimen of Ivermectin in

The post MedinCell begins first Covid-19 clinical study with Ivermectin appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply